Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

被引：3
|
作者：
Zhou, C. [1 ]
Cheng, Y. [2 ]
He, Y. [3 ]
Li, W. [4 ]
Zhang, H. [5 ]
Zhou, Q. [6 ,7 ]
Wang, B. [8 ]
Liu, C. [9 ]
Ramalingam, S. [10 ]
Walding, A. [11 ]
Saggese, M. [11 ]
Wang, J. [12 ]
Fan, M. [12 ]
Wu, Y. [6 ,7 ]
机构：
[1] Tongji Univ, Pulm Hosp, Shanghai, Peoples R China
[2] Jilin Prov Canc Hosp, Thorac Oncol, Changchun, Jilin, Peoples R China
[3] Daping Hosp, Resp Dis, Chongqing, Peoples R China
[4] Jinlin Univ, Hosp 1, Changchun, Jilin, Peoples R China
[5] Forth Mil Med Univ, Tangdu Hosp, Oncol, Xian, Shaanxi, Peoples R China
[6] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[7] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[8] Yangzhou Univ, Subei PeopleS Hosp, Dept Oncol, Yangzhou, Jiangsu, Peoples R China
[9] Xinjiang Med Univ, Tumor Hosp, Urumqi, Peoples R China
[10] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA
[11] Astrazeneca, Global Med Dev, Cambridge, England
[12] Astrazeneca, Global Med Dev, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
osimertinib; China; NSCLC;
D O I：
10.1016/j.jtho.2018.08.669
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-112
引用
收藏
页码：S507 / S508
页数：2
相关论文
共 50 条
  • [1] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
    Ramalingam, S.
    Reungwetwattana, T.
    Chewaskulyong, B.
    Dechaphunkul, A.
    Lee, K. H.
    Imamura, F.
    Nogami, N.
    Ohe, Y.
    Cheng, Y.
    Cho, B. C.
    Cho, E. K.
    Vansteenkiste, J. F.
    Voon, P. J.
    Zhou, C.
    Gray, J.
    Hodge, R.
    Rukazenkov, Y.
    Soria, J-C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Osimertinib (OSI) vs Standard of Care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
    Bischoff, H. G.
    Rueckert, A.
    Reinmuth, N.
    Grohe, C.
    Bohnet, S.
    zum Bueschenfelde, C. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 187 - 187
  • [3] Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis
    Gray, J.
    Okamoto, I.
    Sriuranpong, V.
    Vansteenkiste, J.
    Imamura, F.
    Lee, J. S.
    Pang, Y.
    Cobo, M.
    Kasahara, K.
    Hodge, R.
    Lentrichia, B.
    Dearden, S.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1754 - S1755
  • [4] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
    Planchard, D.
    Boyer, M.
    Lee, J-S.
    Dechaphunkul, A.
    Cheema, P.
    Takahashi, T.
    Todd, A.
    McKeown, A.
    Rukazenkov, Y.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2018, 29 : 169 - 169
  • [5] Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
    Ohe, Yuichiro
    Imamura, Fumio
    Nogami, Naoyuki
    Okamoto, Isamu
    Kurata, Takayasu
    Kato, Terufumi
    Sugawara, Shunichi
    Ramalingam, Suresh S.
    Uchida, Hirohiko
    Hodge, Rachel
    Vowler, Sarah L.
    Walding, Andrew
    Nakagawa, Kazuhiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (01) : 29 - 36
  • [6] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
    Planchard, D.
    Boyer, M.
    Lee, J-S.
    Dechaphunkul, A.
    Cheema, P.
    Takahashi, T.
    Todd, A.
    McKeown, A.
    Rukazenkov, Y.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S72 - S73
  • [7] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset
    Cho, B. C.
    Chewaskulyong, B.
    Lee, K. H.
    Dechaphunkul, A.
    Sriuranpong, V.
    Imamura, F.
    Ohe, Y.
    Nogami, N.
    Kurata, T.
    Okamoto, I.
    Zhou, C.
    Cheng, Y.
    Cho, E. K.
    Jye, V. P.
    Lee, J-S.
    Mann, H.
    Saggese, M.
    Reungwetwattana, T.
    ANNALS OF ONCOLOGY, 2017, 28 : 190 - 190
  • [8] Osimertinib vs standard of care EGFR-TKI as first-line therapy in patients with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
    Grohe, C.
    Bischoff, H.
    Bohnet, S.
    zum Bueschenfelde, Meyer C.
    Reinmuth, N.
    Rueckert, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 269 - 269
  • [9] Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
    Cho, Byoung Chul
    Chewaskulyong, Busayamas
    Lee, Ki Hyeong
    Dechaphunkul, Arunee
    Sriuranpong, Virote
    Imamura, Fumio
    Nogami, Naoyuki
    Kurata, Takayasu
    Okamoto, Isamu
    Zhou, Caicun
    Cheng, Ying
    Cho, Eun Kyung
    Voon, Pei Jye
    Lee, Jong-Seok
    Mann, Helen
    Saggese, Matilde
    Reungwetwattana, Thanyanan
    Ramalingam, Suresh S.
    Ohe, Yuichiro
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (01) : 99 - 106
  • [10] Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis
    Bischoff, H.
    Bohnet, S.
    Reinmuth, N.
    Rueckert, A.
    zum Buschenfelde, Meyer C.
    Hodge, R.
    Rukazenkov, Y.
    Ramalingam, S. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 77 - 77
12345